Get started

Covid19stock

SPHealth 2 Week Comparisons (Oct 7-20 2020)SPHealth - Growth Analysis & Comparison - Cindicator Poll Submission (October 7th - 20th 2020) I've been looking through my Cindicator questions, making forecasts and watching markets as new polls pop up. Here's a comparison chart for 5 major S&P health companies and my rankings forecast. (Descending order from most growth to least) United Health Group Inc (UNH) Abbott Labs (ABT) Johnson & Johnson (JNJ) Pfizer Inc. (PFE) Merck & Co. (MRK) This forecast will be explicitly graded by total growth % comparisons of opening prices on October 7th to closing prices on October 20th across the 5 aforementioned companies. As of right now before 10-9-20 daily market open, the percentage growth is as follows: UNH +1.9% PFE +1.87% JNJ +1.56% ABT +1.1% MRK +0.54% When looking at a specific metric within the already completed duration since I submitted my forecast, overall recent growth is: UNH +2.82% PFE +2.66% JNJ +2.24% MRK +2.22% ABT +1.62% 10-9-20 Forecast Adjustments: Now that I have seen the last 2 days play out, I'm starting to notice a couple things about my forecast and actual live value. I'm confident that United Health will still outperform, but this outlook could change if any major market sell off occurs before the 20th. Pfizer looks like it could be a strong runner up, and I may have flubbed my original forecast by ranking it 4th in growth. Johnson & Johnson is performing approximately as expected. Merck and Abbott Labs could be tricky to pinpoint exactly without some further research and analysis but, I'm guessing that Abbott may come in 4th place if everything settles after any quick rallies that should happen. If a light pump in Merck occurs over the 19th-20th, then there could be a small chance it outperforms Abbott for 4th but it feels like an unlikely scenario. After these deliberations, I've decided my forecast doesn't need much adjusting other than to swap the placement of Pfizer and Abbott. My updated forecast is as follows: United Health Group Inc (UNH) Pfizer Inc. (PFE) Johnson & Johnson (JNJ) Abbott Labs (ABT) Merck & Co. (MRK) One thing to note is that I believe TradingView is not calculating its percentage scale correctly, its placing the 0% Y axis at the close value of the first candle used to calculate growth. So this graph is really just more for me to check my own work by hand, as the percentages on the left will not accurately portray what is actually being graded by Cindicator. I'll check back in after the 20th to see how this turned out! Thanks for tuning in :) Disclaimer, I am not responsible for any losses incurred while attempting to use my data, I hope this can prove to be some sort of learning tool for some and give insight as to how I personally come up with my own numbers. Take into full consideration this could be a completely bad forecast. Cheers
NYSE:UNH
by Hambooger
CHM.C -- Biomedical/Cannabis play trading below cash positionCHM.C is breaking out on record volume! The company had $4M in cash at the end of May. The enterprise value of CHM is about $8.5M. Options (.06, .10) and warrants (.50, .70) were issued at significantly higher levels than current stock price. Insiders and consultants hold over 35% of the float. Cannabis sector is starting to wake up a little but it is the Biomedical angle that has me intrigued about CHM. It has acquired a 16.4% stake ImmunoFlex Therapeutics, the company developing products to enhance immunological responsiveness. It is clear that, once released, they will be marketed in the context of COVID-19 pandemic as preventative and immune system strengthening treatments. While the target date for ImmunoFlex products release was vague (“late Fall 2020”), there are signs that it will come sooner rather than later. On September 28th, ImmunoFlex announced hiring of prominent medical professionals and established a Scientific Advisory Board. I suspect we will be seeing more news very soon. On the Cannabis side of things, CHM has recently expanded its Sugarleaf cultivation facility in Washington State by ~ 30%. They are also in the early stages of establishing a California-based operation.
CLong
by wealth_bakery
1
HLT penutupan cantik minggu ini.1) Selepas melalui fasa kejatuhan 4 hari berturut 25/9-30/9 harga cantik melantun tepat di paras middle BB. 2 )Menarik untuk diperhatikan minggu hadapan dengan harga tutup pada hari jumaat RM1.68 dengan volume masuk meningkat menandakan ramai belian. 3) Jika ia boleh memcahkan bdtl(breakdown trendline) resistance seterusnya ialah RM1.91 Kajian diatas bukanlah bertujuan untuk membeli @ menjual saham, Hanyalah bertujuan untuk pembelajaran sahaja, Berdagang diatas risiko sendiri.
MYX:HLT
by shafiqrosni64
1
XSPA Our patience is running out and ready for a break outFor the past 24 trading days the RSI has been trading in the 20-30 range and yesterday (9/28) is the first day it reached slightly above 40 signaling more confidence than it has in the last month. The volume traded today, Sept. 29 (2.1 million, RSI 41.51) was 3 million less than the day before, Sept. 28 (5.1 million, RSI 44.51) which I am going to assume the bulls shook out the last of the bears. The Bollinger Bands are coming to a squeeze after bouncing around for the whole month of September trading in a tunnel between $1.66-2.12. XSPA needs news... bad. Were tonight's debates about a vaccine enough to push this back above its 50 day trading average of 2.79? XSPA needs GREAT news to push this up 47% so it can begin trading above the 50 DMA, as it has been since August 6 since the last time it traded above the 50 DMA. Current support of 1.66 used to be resistance prior to the news of XSPA contract signing with JFK airport on May 22. The breakout from a bullish flag often results in a powerful move higher, usually measuring the length of the prior flag pole but first this must past resistance (R2) of 2.12. Once this has been achieved, (R3) 3.74, and (R4) 4.74 should soon follow. It is inevitable that business is picking up, people need to travel for work, people WANT a vacation AWAY from home, and airports will forever be accused of being a breeding ground for sickness and disease. There is NO reason XSPA's COVID testing/wellness concept at airports will fail unless it fails internally. Yes, I am a bag holder for now, but you cannot lose if you do not sell. I believe this is a long hold at least until after the election which brings us to holiday travel. If XSPA is operational at all major airports for holiday travelers, just maybe it can break its 52 week high of 8.82
XLong
by VelvetBarbie
Covid US Deaths Technical Analysisidentifying patterns. can see how the mac D on total us deaths is starting to turn bearish, i can see a slowdown happen around election day @ 225000 deaths could peak a few months past into new years @ 285000 deaths before really starting to flatline the squeeze indicator is also showing slowdown in confirmed deaths. we are hitting the top of the ascending wedge, (bearish) the MACD and RSI are both turning bearish as well election and newyears big things are to come. the virus is slowing down as the data shows. I dont care what the news say theres tons of other charts, like confirmed cases and such, but I just like confirmed deaths since the case numbers are not as accurate.
D
by ToddGreen
Small account play with potential upcoming COVID catalystVaccine play: “Four vaccine candidates developed from VXRT's proprietary VAAST platform were assessed in mouse models and elicited a strong immune response.” (finance.yahoo.com) Potential upcoming catalyst of a Phase 1 trial As of last week, down 73% since the yearly high, has begun to reverse. Very oversold on SlowStoch and has been for nearly a month Below 100day SMA, only slightly above 200day SMA Fib targets above, can use 0 fib below for stop loss.
NASDAQ:VXRTLong
by SpinTrades
Genedrive is on the ride 2.0 I am trying to be ultra conservative with my GDR targets here and only assume we are doing a 3 wave move in ABC. This will put us into the £5 region where the C wave extends to x1.618 of the A. Watching the volume closely when we get there and see if the price action will further extend impulsive to stay still an keep on holding. Buying at these levels is not a concern to me at all. Where the top will be thats the only question. Fundamentals are showing £5 is just a realistic target like now, not even with news landed. Keep on accumulating. dyor.
GLong
by tempertrade
RVV.C — FDA Phase 3 Clinical Trials Approval for COVID-19 DrugRevive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19 TORONTO, July 31, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company to proceed with a randomized, double-blind, placebo-controlled confirmatory Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. “The FDA approval of the Phase 3 study to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19 is a tremendous milestone for Revive and I am very proud of the dedication of our team and partners to bring forward a potential new treatment option for patients with a confirmed diagnosis of COVID-19 globally,” said Michael Frank, Revive’s Chief Executive Officer. “We thank the FDA for recognizing the importance of this Phase 3 study and we are now focused on executing on our plans for initiating the clinical trial in an expeditious manner.” About the Phase 3 Confirmatory Clinical Study The Phase 3 confirmatory clinical study titled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19”, will enroll up to 1,000 patients that will be randomized 1:1:1 to receive Bucillamine 100 mg three times a day (“TID”), Bucillamine 200 mg TID or placebo TID for up to 14 days. The primary objective is to compare frequency of hospitalization or death in patients with mild-moderate COVID-19 receiving Bucillamine therapy with those receiving placebo. The primary endpoint is the proportion of patients meeting a composite endpoint of hospitalization or death from the time of first dose through Day 28 following randomization. Efficacy will be assessed by comparison of clinical outcome (death or hospitalization), disease severity using the 8-category NIAID COVID ordinal scale, supplemental oxygen use, and progression of COVID‑19 between patients receiving standard-of-care plus Bucillamine (high dose and/or low dose) and patients receiving standard-of-care plus placebo. Safety will be assessed by reported pre-treatment adverse events and treatment-emergent adverse events (including serious adverse events and adverse events of special interest), laboratory values (hematology and serum chemistry), vital signs (heart rate, respiratory rate, and temperature), and peripheral oxygen saturation. An interim analysis will be performed by an Independent Data and Safety Monitoring Board (“DSMB”) after 210 patients have been treated and followed up for a total of 28 days after randomization. The better performing Bucillamine dose at the interim analysis will be selected and patients will then be randomized 2:1 to the selected Bucillamine dose or placebo. Additional interim analyses will be performed after 400, 600, and 800 patients have reached this same post-treatment timepoint. The independent DSMB will actively monitor interim data for the ongoing safety of patients and will recommend continuation, stopping or changes to the conduct of the study based on the interim analysis reports. Scientific Rationale of Bucillamine for COVID-19 Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via increasing glutathione activity and other anti-inflammatory activity, to lessen the destructive consequences of SARS-CoV2 infection in the lungs and attenuate the clinical course of COVID-19. The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.
CSE:RVVLong
by wealth_bakery
VST.C -- Gearing up for Wave 2 up move on COVID-19 newsVST has its hand in a number of sectors, including a sizeable holding in FANS (esports/gambling stock) but it has recently gained attention because of its stake in the rapid COVID-19 test manufacturer. Yesterday, they've announced that they are increasing their manufacturing capacity by 5M test kits per month. In the followup webinar, investors were informed of several pending orders with large corporate and government bodies. The company is under NDA at the moment but there will be followup news releases as the orders are fulfilled. Their COVID-19 test has received authorization in a number of major jurisdictions, including most recently Brazil which faces one of the worst COVID-19 outbreaks at the moment. The company reported record numbers in most recent financials, nearly doubling its net income ($4.7M) from the same 6 month period of last year. Technically, yesterday marked a decisive reversal after ~50% retrace from recent high and it appears the chart is gearing up for Wave 2 move that should see re-test (and likely break) through resistance around 1.10. ---------------------------------------------------------------- Victory Square Health Increases Monthly Production of Rapid Covid-19 Test Kits to Meet Increased Demand with New Manufacturing Agreement with Gold Analisa Diagnostica Ltda VANCOUVER, British Columbia, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Victory Square Health Inc./Safetest (“VS Health” or the "Company") – portfolio company of Victory Square Technologies Inc. ("Victory Square") (CSE:VST) (OTC:VSQTF) (FWB:6F6) – is pleased to announce entering into a manufacturing contract for their IgG and IgM Rapid Test Kits for the detection of Covid-19 for sales and distribution globally. The latest manufacturing agreement will allow the company to produce an additional 5,000,000 VS Health Covid-19 Rapid Tests monthly for Global distribution. This additional manufacturing contract will also enable the Company to enter into additional global sales agreements in various industries which have shown interest, including retail, hospitality, pharmaceutical, correctional facilities, casino, border services, education, airport, military, government, and more. “Based on our outreach and discussions, the demand for our exclusive test from distributors around the world is very high,” said Victory Square Health CEO Felipe Peixoto. “Given that demand, this new capacity-building manufacturing contract is a significant boost to our plan to be a positive solution around the world. To that end, Victory Square Health is committed to providing assistance to as many nations as possible through these distribution channels.” The new Victory Square Health/Safetest manufacturer is Gold Analisa Diagnostica Ltda., a Government-recognized manufacturer of bio products in Brazil and has operated for over 30 years. Gold Analisa is ISO 9001: 2015 certified by DNV - DET NORSKE VERITAS in the scope of production, marketing and technical-scientific advisory services for products for in vitro diagnostic use. Gold Analisa has Anvisa's Good Manufacturing and Control Practices certificate with hivital, and also participates in the PNCQ - National Quality Control Program, sponsored by SBAC – Sociedade Brasileira de Análises Clínicas. Gold Analisa has a distribution network that aims to be close to customers, covering the entire national territory of Brazil. “We’re completely energized by this critical new manufacturing contract which will allow Victory Square Health to fulfill the tremendous demand for its exclusive Rapid Test kits on a global scale,” said Shafin Diamond Tejani, CEO of Victory Square Technologies, of which Victory Square Health is a portfolio company. “We are actively working together on other production partnership agreements to further increase our production capacity.”
CSE:VSTLong
by wealth_bakery
BioNTech Stock Will Soar With Its First-Mover Vaccine AdvantageNASDAQ:BNTX a German company and its american partner NYSE:PFE will likely have a first-mover advantage in the coronavirus vaccine race in the U.S. This will affect both stocks, once the final vaccine results are in. Assuming the bottom is in and we are about to continue the Trend as previously, im expecting a big move after the approval, so dont forget to take risk of the table! The reason for this is that the two companies are expecting to be the first to produce large-scale results from their Phase 2/3 clinical trials in October, according to Barron’s. Depending on how effective their vaccine is, the U.S. Food and Drug Administration may even grant it emergency-use authorization The advantage of their trial is that it is large, involving more than 30,000 participants. The FDA wants to see at least 50% efficacy in trials before granting any Covid-19 authorization. Why BioNTechs Vaccine Looks Like a Winner With Pfizer in the back FDA and President Donald Trump are likely to move quickly. According to them even the first small study with 24 Persons that took their messenger RNA vaccine produced antibodies. With a lower doses usage of the vaccine and developed antibodies after 28 days — at levels about two times higher than in normal, recovering Covid-19 patients. BioNTech and Fosun Pharma to Potentially Supply 10 Million Doses of BioNTech’s BNT162 to Hong Kong SAR and Macao SAR Also a Deal to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidat This combined with the huge buying volume and market shifts will grant momentum for bigger goals. Just think about what ccould happen when they get kinda a monopol situation going for them. Thank you for take the time and reading this and as always stay storng in those shaky times! Sebastian
NASDAQ:BNTXLong
by Sebastian-TradingExpertsEU
4
KNR.C -- Breakout on lab validation of COVID-19 detection techUndervalued and overlooked company, in my opinion with the a successful energy efficiency and management line of products with partners like Toyota, Beyond Meat, Brookfield and others. Cash flow positive. $41M mkt cap and 31M float with 45% insider ownership. Only getting noticed now, after introducing Biocloud virus detection tech that is undergoing testing for real-time detection of COVID-19 in enclosed spaces. Today marked an important first step - lab validation - but there's more to come. Next week, we should expect the news of testing using COVID-19. Lots of hype, certainly, but the fundamental strength of this business is undeniable. Kontrol’s COVID-19 Technology Prototype Receives Positive Lab Test Results TORONTO, ON / ACCESSWIRE / August 27, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) ("Kontrol" or "Company") is pleased to announce that the Kontrol BioCloud (or "BioCloud") fully functioning prototype was able to operate in real-time and has received positive lab test results. "Following lab testing, we have demonstrated that our fully operating prototype, previously announced on August 10, 2020, can detect COVID-19 specific components in air samples under a controlled experiment," says Paul Ghezzi, Chief Executive Officer of Kontrol. "This was a critical milestone that we achieved as it ensures the safety and operating capability of BioCloud and we can now move quickly to testing against the live aerosolized COVID-19 virus. We remain on track with achieving our specific milestones and anticipate live COVID-19 virus testing during the week of August 31." The controlled testing was conducted by the lab of independent consultant, Dr. David Heinrichs, PhD (Heinrichs Laboratory) - experts in the study of Microbiology and Immunology. Next Major Milestones The company has now tested both its proprietary detection chamber as announced on August 19, 2020 and its fully operating prototype. Following testing with the live COVID-19 virus, the Company anticipates that it will be in a position to move to commercialization and production of operating units shortly thereafter. We continue to fund all BioCloud technology development through internal cash generation and Kontrol will not raise capital to complete testing and pre-commercialization work. When testing against the live COVID-19 virus the Company seeks to establish the lower detection limits of BioCloud and set final parameters for applications based on room size and number of individuals. These lower detection limits will be part of commercialization specifications. Commercialization Plans "We are excited to have a working prototype and a successful result given all the hard work that has gone into the BioCloud," says Gary Saunders VP of Kontrol. "We have sourced all the components required for commercialization and have our supply chain ready to go. The Canadian Government has recently announced $2 billion in federal funding to help schools reopen safely. BioCloud has the potential to be an important tool in creating safe spaces by seeking to detect for the virus and assessing the effectiveness of HVAC system improvements by continuously sampling air in real-time." The Company anticipates a selling price in the range of $12,000 US per BioCloud unit based on the current supply chain components. The detection chamber is replaceable and represents a potential secondary source of commercialized revenue for Kontrol. Any time the detection chamber comes into contact with the COVID virus it must be disposed of safely and replaced. New Applications beyond COVID-19 During testing the Company has determined that BioCloud has the capability to detect other airborne viruses in addition to COVID-19. This determination was made based on working with the independent lab consultants and a review of the detection mechanism and specifications. While COVID-19 is the most pressing concern for creating safe spaces, other airborne viruses may have similar characteristics that BioCloud may be able to detect. About Kontrol BioCloud BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. About Kontrol Energy Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions. Kontrol Energy is one of Canada's fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean's.
K
by wealth_bakery
1
WAVE.V -- Bottoming Out Undervalued Pharma/COVID-19 PlayThe most attractive part of WAVE.V is share structure: 54M total float with 41M shares held by insiders / escrowed, leaving about 13M shares free trading. The company owns a portfolio of generic oncology drugs from which it generates over $300K of quarterly revenue. $1M in cash on hand. Based on last financials, they are $83K away from generating positive cash flow and recent developments suggest they will get there sooner rather than later: -- Received grant to develop a rapid COVID-19 saliva based test in partnership with the University of Manitoba -- Received authorization from several EU countries to expand sales of their generic oncology drugs -- Expecting FDA authorization in Q4 2020 At below $10M mkt cap and in the absence of any cheap paper overhang, I feel that this is a tremendous opportunity. Compare it to something like THRM.V which is developing a similar saliva-based COVID-19 test, has next to nothing in revenues, a ton of cheap paper, 3x the float and 3x the market cap, and you realize that current valuation makes no sense. Chart suggests the stock is reversing from short term downtrend after finding bottom at .15. A doji, followed by green candle on increased volume and EMA 20 crossing above EMA 50 providing additional support at .16. Today was a pullback on lower volume that resulted in a higher low. I used it as an opportunity to pad my position. Next catalysts that could propel sp to significantly higher levels are updates on the oncology drug sales in Europe, rapid COVID-19 test development progress and FDA approval of oncology drugs for sale/marketing in the US.
WLong
by wealth_bakery
SONA.C -- Potential bounce opportunity from historical supportSONA shaved off close to 60% off its recent highs after news of 2 week delay for FDA approval of their COVID-19 test kits. Nothing has changed fundamentally and, if you read the NR carefully, they are lining up more customers and shipping kit prototypes under research license. NASDAQ uplisting is pending as well. The stock has landed in the historical support zone, almost exactly at EMA 50. Additional Fib support right below. This is a good speculative entry here for a bounce with multiple catalysts pending. A stop just below Fib. support may be a good idea.
CSE:SONALong
by wealth_bakery
3